



## PRESS RELEASE

*Submitted for disclosure on 4 October 2016 at 12.00 (CET).*

*The information in this press release is not intended for distribution, publication or public release, directly or indirectly, in or into Australia, Canada, Japan, the United States or any other jurisdiction where the publication or distribution of this press release may be unlawful.*

## Probi publishes prospectus

**The prospectus relating to Probi's rights issue of approximately SEK 602 million has been approved and registered by the Swedish Financial Supervisory Authority and is now available on the Company's website [www.probi.com](http://www.probi.com). The prospectus and a pre-printed issue statement will be sent by mail to Probi's directly registered shareholders in Sweden.**

The prospectus and application forms for subscription without preferential right can be obtained from Probi and Handelsbanken. The prospectus and application forms for subscription without preferential right will also be available on Probi's website [www.probi.se/en/investor-relations/rights-issue-2016](http://www.probi.se/en/investor-relations/rights-issue-2016) and on Handelsbanken's website [www.handelsbanken.se/investeringserbjudande](http://www.handelsbanken.se/investeringserbjudande) (only in Swedish).

Handelsbanken Capital Markets is acting as financial advisor and Mannheimer Swartling Advokatbyrå AB is acting as legal advisor to Probi in relation to the rights issue.

### FOR FURTHER INFORMATION, CONTACT:

Peter Nählstedt, CEO, Probi, tel +46 46 286 89 23, e-mail: [peter.nahlstedt@probi.se](mailto:peter.nahlstedt@probi.se)  
Niklas Brandt, CFO, Probi, tel +46 46 286 89 26, e-mail: [niklas.brandt@probi.se](mailto:niklas.brandt@probi.se)

### ABOUT PROBI

*Probi AB is a Swedish publicly traded bioengineering company that develops effective and well-documented probiotics. Through its world-leading research, Probi has created a strong product portfolio in the gastrointestinal health and immune system niches. Probi's products are available to consumers in more than 30 countries worldwide. Probi's customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. In 2015 Probi had sales of MSEK 216. The Probi share is listed on Nasdaq Stockholm, Small Cap. Probi has about 4,400 shareholders. Read more at [www.probi.se](http://www.probi.se).*



## IMPORTANT NOTICE

The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares, subscription rights or other securities in Probi. Any invitation to the persons concerned to subscribe for shares in Probi will only be made through the prospectus which Probi publishes on 4 October 2016.

This press release may not be released, published or distributed, directly or indirectly, in or into Australia, Japan, Canada, the United States or any other jurisdiction where participation would require additional prospectuses, registration or measures besides those required by Swedish law. Nor may this press release be distributed in or into such countries or any other country or jurisdiction in which distribution requires such measures or otherwise would be in conflict with applicable regulations. Any failure to comply with the restrictions described may result in a violation of applicable securities regulations.

No subscription rights, paid subscribed shares or shares in Probi have been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act") or the securities legislation of any state or other jurisdiction in the United States and no subscription rights, paid subscribed shares or shares may be offered, subscribed for, sold, resold, delivered or otherwise transferred, directly or indirectly, in or into the United States except under an available exemption from, or transaction not subject to, the registration requirements under the Securities Act and in compliance with the securities legislation in the relevant state or any other jurisdiction of the United States. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States.

This press release contains certain forward-looking information that reflects Probi's present view of future events as well as financial and operational development. Words such as "intend", "assess", "expect", "may", "plan", "believe", "estimate" and other expressions entailing indications or predictions of future development or trends, not based on historical facts, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties as it depends on future events and circumstances. Forward-looking information is not a guarantee of future results or development and actual outcomes may differ materially from the statements set forth in the forward-looking information.